Company Overview and News

Can RCE Capital keep up its solid growth?

2018-09-25 theedgemarkets
IT will be tough for non-bank financial institution RCE Capital Bhd to maintain its lending growth as strongly as it has done in the past given the growing challenges ahead.
9296 BKRKF

RCE Capital’s FY19 loan growth benchmarked against banks’ 5%

2018-09-07 theedgemarkets
KUALA LUMPUR: General loan financing services provider RCE Capital Bhd, which provides consumer financing to civil servants, said it is benchmarking its loan growth this year against the banking industry’s average.

KLCI seen under pressure, to track global markets

2018-09-06 theedgemarkets
KUALA LUMPUR (Sept 7): The FBM KLCI seen under pressure today, in line with the overnight decline at most global markets.
0154 5347 5115 0145 9296 TNABY 0107 TNABF 7123

Priceworth, TFP Solutions, TNB, FGV, Alam Maritim, MMC Corp, iDimension, Eduspec, RCE Capital and EA Holdings

2018-09-06 theedgemarkets
KUALA LUMPUR (Sept 6): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (Sept 7) may include the following: Priceworth International Bhd, TFP Solutions Bhd, Tenaga Nasional Bhd, FGV Holdings Bhd, Alam Maritim Resources Bhd, MMC Corp Bhd, iDimension Consolidated Bhd, Eduspec Holdings Bhd, RCE Capital Bhd and EA Holdings Bhd.
0154 5347 5115 0145 9296 TNABY 0107 RCL TNABF BSMAF 7123 1818

RCE Cap benchmarks FY19 loan growth to banks' average of 5%

2018-09-06 theedgemarkets
KUALA LUMPUR (Sept 6): General loan financing services provider RCE Capital Bhd said it is benchmarking its loan growth this year against that set by other banks.

RCE Capital's 1Q profit strengthens on steady consumer loan growth

2018-08-23 theedgemarkets
KUALA LUMPUR (Aug 23): RCE Capital Bhd's net profit for the first quarter ended June 30, 2018 (1QFY19) grew 11% to RM23.2 million from RM20.93 million a year earlier, on higher interest income arising from steady loan growth in its consumer financing segment.

Making money from money

With loan growth on the rise after four years of slowing, and Bank Negara data showing that Malaysia is finally on track to accelerate in 2018, one of the best sectors to look at will be credit and money-lending companies.
9296 1171 BKRKF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...